Retrospective Database Analysis Evaluating the Clinical Outcomes of Changing Treatment of People with Type 2 Diabetes Mellitus (T2DM) from Other DPP-4 Inhibitor Therapy to Alogliptin in a Primary Care Setting

INTRODUCTION: Although some differences between individual dipeptidyl peptidase-4 (DPP-4) inhibitors may exist, the National Institute for Health and Clinical Excellence (NICE) have recommended that ‘prescribers should be encouraged to select the individual DPP-4 inhibitor with the lowest acquisitio...

Descripción completa

Detalles Bibliográficos
Autores principales: Strain, W. David, McEwan, Phil, Howitt, Heena, Meadowcroft, Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6612350/
https://www.ncbi.nlm.nih.gov/pubmed/31264097
http://dx.doi.org/10.1007/s13300-019-0662-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6612350/
https://www.ncbi.nlm.nih.gov/pubmed/31264097
http://dx.doi.org/10.1007/s13300-019-0662-y

Ejemplares similares